A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

<p>Abstract</p> <p>Background</p> <p>To compare the activity and toxicity of docetaxel/carboplatin (DC) doublet vs single agent docetaxel (D) as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC).</p> <p>Methods</p> <...

Full description

Bibliographic Details
Main Authors: Pavlakou Georgia, Kentepozidis Nikolaos, Syrigos Kostas, Varthalitis Ioannis, Agelidou Athina, Agelaki Sophia, Pallis Athanasios G, Kotsakis Athanasios, Kontopodis Emmanouel, Georgoulias Vassilis
Format: Article
Language:English
Published: BMC 2010-11-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/10/633

Internet

http://www.biomedcentral.com/1471-2407/10/633

Similar Items